MGTA
Income statement / Annual
Last year (2024), Magenta Therapeutics, Inc.'s total revenue was $6.24 M,
and the percentage change from the previous year is not available.
In 2024, Magenta Therapeutics, Inc.'s net income was -$84.97 M.
See Magenta Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$6.24 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$83.11 M
|
$55.14 M
|
$46.77 M
|
$50.62 M
|
$59.21 M
|
$41.34 M
|
$27.90 M
|
$5.78 M
|
| General & Administrative Expenses |
$24.99 M
|
$25.76 M
|
$27.93 M
|
$28.09 M
|
$23.76 M
|
$18.62 M
|
$7.83 M
|
$3.49 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$24.99 M
|
$25.76 M
|
$27.93 M
|
$28.09 M
|
$23.76 M
|
$18.62 M
|
$7.83 M
|
$3.49 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$108.10 M
|
$80.90 M
|
$74.69 M
|
$78.70 M
|
$82.97 M
|
$59.96 M
|
$35.73 M
|
$9.27 M
|
| Cost And Expenses |
$0.00
|
$80.90 M
|
$74.69 M
|
$78.70 M
|
$82.97 M
|
$59.96 M
|
$35.73 M
|
$9.27 M
|
| Interest Income |
$17.37 M
|
$0.00
|
$3.56 M
|
$3.77 M
|
$0.00
|
$2.45 M
|
$236.00 K
|
$0.00
|
| Interest Expense |
$0.00
|
-$4.44 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$163.00 K
|
| Depreciation & Amortization |
$0.00
|
$1.93 M
|
$2.02 M
|
$1.98 M
|
$1.84 M
|
$875.00 K
|
$376.00 K
|
$6.00 K
|
| EBITDA |
-$101.86 M |
-$78.98 M |
-$74.69 M |
-$78.70 M |
-$82.97 M |
-$59.96 M |
-$35.12 M |
-$9.26 M |
| EBITDA Ratio |
-16.34
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-16.34
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$16.90 M
|
$4.44 M
|
$3.56 M
|
$3.77 M
|
$6.20 M
|
$2.45 M
|
$236.00 K
|
-$163.00 K
|
| Income Before Tax |
-$84.97 M
|
-$76.46 M
|
-$71.14 M
|
-$74.94 M
|
-$76.77 M
|
-$57.52 M
|
-$35.49 M
|
-$9.43 M
|
| Income Before Tax Ratio |
-13.63
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$4.44 M
|
-$5.58 M
|
-$5.74 M
|
-$8.04 M
|
$0.00
|
$236.00 K
|
$0.00
|
| Net Income |
-$84.97 M
|
-$72.02 M
|
-$65.56 M
|
-$69.19 M
|
-$68.73 M
|
-$57.52 M
|
-$35.49 M
|
-$9.43 M
|
| Net Income Ratio |
-13.63
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-21.75 |
-23.05 |
-1.12 |
-1.43 |
-1.75 |
-59.42 |
-1.65 |
-0.44 |
| EPS Diluted |
-21.75 |
-23.05 |
-1.12 |
-1.43 |
-1.75 |
-59.42 |
-1.65 |
-0.44 |
| Weighted Average Shares Out |
$3.91 M
|
$3.12 M
|
$58.79 M
|
$48.46 M
|
$39.22 M
|
$967.87 K
|
$21.50 M
|
$21.50 M
|
| Weighted Average Shares Out Diluted |
$3.91 M
|
$3.12 M
|
$58.79 M
|
$48.46 M
|
$39.22 M
|
$967.87 K
|
$21.50 M
|
$21.50 M
|
| Link |
|
|
|
|
|
|
|
|
